Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Cytogen halts autologous lymphocyte therapy program

March 27, 1998

Coulter completes patient enrollment in Bexxar phase III trial

March 25, 1998

Phase II ImmTher trial begins in pediatric cancer patients

March 19, 1998

Cel-Sci expands North American clinical trial for Multikine

March 18, 1998

Ribi ImmunoChem and Schering-Plough sign distribution agreement for Melacine

March 18, 1998

Techniclone to begin TNT clinical trials using unique delivery system

March 16, 1998

Genentech and DAKO establish development agreement for HER2 detection

March 13, 1998

Patient enrollment completed for phase I/II pancreatic cancer trial

March 13, 1998

Avicidin advances to phase II

March 5, 1998

DiagnoCure signs agreements related to development of targeted nanoerythrosomes

March 4, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...